Last quarter (Q4 2023), Relmada Therapeutics's total revenue was $-96.40K, a decrease of -Infinity% from the same quarter last year. In Q4, Relmada Therapeutics's net income was $-25.17M. See Relmada Therapeutics’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 23	Dec 22	Dec 21	Dec 20	Jun 19
Total Revenue	-	-	-	-	$ 0.00	$ 0.00
Cost of Revenue	$ 29.22M	-	-	-	-	-
Gross Profit	$ -29.22M	-	-	-	-	-
Operating Expense	$ -17.33M	$ 103.70M	$ 161.25M	$ 125.70M	$ 60.84M	$ 12.73M
Operating Income	$ -60.07M	$ -103.70M	$ -161.25M	$ -125.70M	$ -60.84M	$ -12.73M
Net Non Operating Interest Income Expense	$ 10.22M	$ 5.15M	$ 2.66M	$ 1.20M	$ 1.40M	$ -761.04K
Other Income Expense	$ -42.00K	$ 241.16K	$ 4.81M	$ 1.25M	$ -16.95K	$ -3.83M
Pretax Income	$ -55.13M	$ -98.79M	$ -157.04M	$ -125.75M	$ -59.46M	$ -17.32M
Tax Provision	$ 82.41M	$ 88.61M	$ 6.20M	$ 0.00	-	-
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	$ -55.13M	$ -98.79M	$ -157.04M	$ -125.75M	$ -59.46M	$ -17.32M
Basic EPS	-	-	-	-	$ -3.81	$ -2.74
Diluted EPS	-	-	-	-	$ -3.81	$ -2.74
Basic Average Shares	-	-	-	-	$ 15.59M	$ 6.31M
Diluted Average Shares	-	-	-	-	$ 15.59M	$ 6.31M
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-	-
Total Expenses	$ 11.89M	$ 103.70M	$ 161.25M	$ 125.70M	$ 60.84M	$ 12.73M
Net Income From Continuing And Discontinued Operation	$ -111.43M	$ -98.79M	$ -157.04M	$ -125.75M	$ -59.46M	$ -17.32M
Normalized Income	$ -37.26M	$ -78.05M	$ -130.42M	-	$ -59.44M	$ -13.49M
Interest Expense	-	-	-	-	-	-
EBIT	$ -65.17M	$ -103.94M	$ -159.70M	$ -126.95M	$ -60.84M	$ -12.73M
EBITDA	$ -65.17M	$ -103.94M	$ -159.70M	$ -126.95M	$ -60.83M	$ -12.72M

Currency in USD

Relmada Therapeutics Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing